A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement

New England Journal of Medicine

Volumn 337, Issue 19, 1997, Pages 1329-1335

  Eriksson, Bengt I ^a   Wille Jørgensen, Peer ^b   Kälebo, Peter ^a   Mouret, Patrick ^c   Rosencher, Nadia ^d   Bösch, Peter ^e   Baur, Markus ^f   Ekman, Steffan ^f   Bach, Doris ^f   Lindbratt, Siv ^g   Close, Philippe ^f  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b BISPEBJERG HOSPITAL   (Denmark)

^c GOETHE UNIVERSITY   (Germany)

^d Hôpital Cochin ^*  (France)

^e Abteilung Anasthesie Intensivmedizin   (Austria)

^f NOVARTIS PHARMA AG   (Switzerland)

^g Novartis   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DESULFATOHIRUDIN; ENOXAPARIN; LEPIRUDIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; DOUBLE-BLIND METHOD; ENOXAPARIN; FEMALE; HIRUDIN THERAPY; HIRUDINS; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECOMBINANT PROTEINS; THROMBOPHLEBITIS; TREATMENT OUTCOME;

EID: 0030722727     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199711063371901     Document Type: Article

References (23)

1. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
2. Kaiser B, Markwardt F. Antithrombotic and haemorrhagic effects or synthetic and naturally occurring thrombin inhibitors. Thromb Res 1986; 43:613-20.
3. Talbot MD, Ambler J, Butler KD, et al. Recombinant desulphatohirudin (CGP 39393): comparative studies with standard and low molecular weight heparin. In: Zilla P, Fasol R, Callow A, eds. Applied cardiovascular biology. Vol 1. Basel, Switzerland: S. Karger, 1990:131-46.
4. Eriksson BI, Ekman S, Kälebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996;347:635-9.
5. Eriksson BI, Ekman S, Lindbratt S, et al. Prevention of thromboembolism with use of recombinant hirudin: results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 1997;79:326-33.
6. Nurmohamed MT, Rosendaal FR, Büller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:152-6.
7. Leizorovicz A, Haugh MC, Chapuis F-R, Samana MM, Boissel J-P. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992;305:913-20.
8. Jørgensen LN, Wille-Jørgensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Br J Surg 1993;80:689-704.
9. Good clinical practice for trials on medicinal products in the European community. Good Clin Pract J 1994;1:Suppl.
10. Biello DR, Mattar AG, McKnight RC, Siegel BA. Ventilation-perfusion studies in suspected pulmonary embolism. AJR Am J Roentgenol 1979;133:1033-7.
11. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972;104:134-44.
12. Kälebo P, Anthmyr BA, Eriksson BI, Zachrisson BE. Optimization of ascending phlebography of the leg for screening of deep vein thrombosis in thromboprophylactic trials. Acta Radiol 1997;38:320-6.
13. Kälebo P, Ekman S, Lindbratt S, et al. Percentage of inadequate phlebograms and observer agreement in thromboprophylactic multicenter trials using standardized methodology and central assessment. Thromb Haemost 1996;76:893-6.
14. Casagrande JT, Pike MC, Smith PG. An improved approximate formula for calculating samples sizes for comparing two binomial distributions. Biometrics 1978;34:483-6.
15. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992;305:567-74.
16. Nicolaides AN, Arcelus J, Belcaro G, et al. Prevention of venous thromboembolism. Int Angiol 1992;11:151-9.
17. Clagett GP, Anderson FA Jr, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995;108:Suppl:312S-334S.
18. Colwell CW Jr, Spiro TE. Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty. Clin Orthop 1995;319:215-22.
19. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329:1370-6.
20. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomization trials in general, orthopedic, and urologic surgery. N Engl J Med 1988;318: 1162-73.
21. Havig Ö. Deep vein thrombosis and pulmonary embolism: an autopsy study with multiple regression analysis of possible risk factors. Acta Chir Scand Suppl 1977;478:1-120.
22. Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med 1981;94:439-44.
23. Eriksson BI, Kälebo P, Anthmyr BA, Wadenvik H, Tengborn L, Risberg B. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement: comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am 1991;73:484-93.